Skip to main content
Top
Published in: Diabetologia 2/2008

01-02-2008 | Article

Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study

Authors: A. Jeandrot, J.-L. Richard, C. Combescure, N. Jourdan, S. Finge, M. Rodier, P. Corbeau, A. Sotto, J.-P. Lavigne

Published in: Diabetologia | Issue 2/2008

Login to get access

Abstract

Aims/hypothesis

Infection of diabetic foot ulcers is common; at early stages it is difficult to differentiate between non-infected ulcers (or those colonised with normal flora) and ulcers infected with virulent bacteria that lead to deterioration. This pilot study aimed to assess the diagnostic accuracy of inflammatory markers as an aid to making this distinction.

Methods

We included 93 diabetic patients who had an episode of foot ulcer and had not received antibiotics during the 6 months preceding the study. Ulcers were classified as infected or uninfected, according to the Infectious Diseases Society of America–International Working Group on the Diabetic Foot classification. Diabetic patients without ulcers (n = 102) served as controls. C-reactive protein (CRP), orosomucoid, haptoglobin and procalcitonin were measured together with white blood cell and neutrophil counts. The diagnostic performance of each marker, in combination (using logistic regression) or alone, was assessed.

Results

As a single marker, CRP was the most informative for differentiating grade 1 from grade 2 ulcers (sensitivity 0.727, specificity 1.000, positive predictive value 1.000, negative predictive value 0.793) with an optimal cut-off value of 17 mg/l. In contrast, white blood cell and neutrophil counts were not predictive. The most relevant combination derived from the logistic regression was the association of CRP and procalcitonin (AUC 0.947), which resulted in a significantly more effective determination of ulcer grades, as shown by comparing receiver operating characteristic curves.

Conclusions/interpretation

Measurement of only two inflammatory markers, CRP and procalcitonin, might be of value for distinguishing between infected and non-infected foot ulcers in subgroups of diabetic patients, to help ensure the appropriate allocation of antibiotic treatment. Nevertheless, external validation of the diagnostic value of procalcitonin and CRP in diabetic foot ulcers is needed before routine use can be recommended.
Literature
1.
go back to reference Cavanagh PR, Lipsky BA, Bradbury AW, Botek G (2005) Treatment for diabetic foot ulcers. Lancet 366:1725–1735PubMedCrossRef Cavanagh PR, Lipsky BA, Bradbury AW, Botek G (2005) Treatment for diabetic foot ulcers. Lancet 366:1725–1735PubMedCrossRef
2.
go back to reference Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM (1998) Preventive foot care in people with diabetes. Diabetes Care 21:2161–2177PubMedCrossRef Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM (1998) Preventive foot care in people with diabetes. Diabetes Care 21:2161–2177PubMedCrossRef
3.
go back to reference Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 336:1719–1724CrossRef Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 336:1719–1724CrossRef
4.
go back to reference Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA (2006) Risk factors for foot infections in individuals with diabetes. Diabetes Care 29:1288–1293PubMedCrossRef Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA (2006) Risk factors for foot infections in individuals with diabetes. Diabetes Care 29:1288–1293PubMedCrossRef
5.
go back to reference Frykberg RG, Zgonis T, Armstrong DG et al (2006) Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg 45:S1–S66PubMedCrossRef Frykberg RG, Zgonis T, Armstrong DG et al (2006) Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg 45:S1–S66PubMedCrossRef
6.
7.
go back to reference Lipsky BA, Berendt AR, Deery HG et al (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910PubMedCrossRef Lipsky BA, Berendt AR, Deery HG et al (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910PubMedCrossRef
8.
go back to reference Lipsky BA (2004) A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20:S68–S77PubMedCrossRef Lipsky BA (2004) A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20:S68–S77PubMedCrossRef
9.
go back to reference Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA (2007) Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system. Clin Infect Dis 44:562–567PubMedCrossRef Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA (2007) Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system. Clin Infect Dis 44:562–567PubMedCrossRef
10.
go back to reference Armstrong DG, Perales TA, Murff RT, Edelson GW, Welchon JG (1996) Value of white blood cell count with differential in the acute diabetic foot infection. J Am Podiatr Med Assoc 86:224–227.PubMed Armstrong DG, Perales TA, Murff RT, Edelson GW, Welchon JG (1996) Value of white blood cell count with differential in the acute diabetic foot infection. J Am Podiatr Med Assoc 86:224–227.PubMed
11.
go back to reference Eneroth M, Apelqvist J, Stenstrom A (1997) Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 18:716–722PubMed Eneroth M, Apelqvist J, Stenstrom A (1997) Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 18:716–722PubMed
12.
go back to reference Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef
13.
go back to reference Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef
14.
go back to reference Hammer S, Meisner F, Dirschedl P, Hammer C (1998) Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 6:235–241PubMedCrossRef Hammer S, Meisner F, Dirschedl P, Hammer C (1998) Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 6:235–241PubMedCrossRef
15.
go back to reference Kordek A, Podraza W, Czajka R (2006) Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates. Diagn Microbiol Infect Dis 56:31–34PubMedCrossRef Kordek A, Podraza W, Czajka R (2006) Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates. Diagn Microbiol Infect Dis 56:31–34PubMedCrossRef
16.
go back to reference Lavery LA, Armstrong DG, Peters EJ, Lipsky BA (2007) Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes Care 30:270–274PubMedCrossRef Lavery LA, Armstrong DG, Peters EJ, Lipsky BA (2007) Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes Care 30:270–274PubMedCrossRef
17.
go back to reference Steinbach G, Rau B, Debard AL et al (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor system. Clin Chem Lab Med 42:440–449PubMedCrossRef Steinbach G, Rau B, Debard AL et al (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor system. Clin Chem Lab Med 42:440–449PubMedCrossRef
18.
go back to reference Zhou XH, Obuchowski NA, McClish DK (2002) Statistical methods in diagnostic medicine, Wiley & Sons, New York, pp 198–200 Zhou XH, Obuchowski NA, McClish DK (2002) Statistical methods in diagnostic medicine, Wiley & Sons, New York, pp 198–200
19.
go back to reference Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed
20.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef
21.
go back to reference Rothenburger M, Markewitz A, Lenz T et al (1999) Detection of acute phase response and infection: the role of procalcitonin. Clin Chem Lab Med 37:275–279PubMedCrossRef Rothenburger M, Markewitz A, Lenz T et al (1999) Detection of acute phase response and infection: the role of procalcitonin. Clin Chem Lab Med 37:275–279PubMedCrossRef
22.
go back to reference Edmonds M (2005) Infection in the neuroischemic foot. International Journal of Lower Extremity Wounds 4:145–153PubMedCrossRef Edmonds M (2005) Infection in the neuroischemic foot. International Journal of Lower Extremity Wounds 4:145–153PubMedCrossRef
23.
go back to reference Bowler PG, Duerden BI, Armstrong DG (2001) Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 14:244–269PubMedCrossRef Bowler PG, Duerden BI, Armstrong DG (2001) Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 14:244–269PubMedCrossRef
24.
go back to reference Serena T, Robson MC, Cooper DM, Ignatius J, on behalf of the Human Genome Sciences Clinical Trial Group (2006) Lack of reliability of clinical/visual assessment of chronic wound infection: the incidence of biopsy-proven infection in venous leg ulcers. Wounds 18:197–202 Serena T, Robson MC, Cooper DM, Ignatius J, on behalf of the Human Genome Sciences Clinical Trial Group (2006) Lack of reliability of clinical/visual assessment of chronic wound infection: the incidence of biopsy-proven infection in venous leg ulcers. Wounds 18:197–202
25.
go back to reference Xu L, McLennan SV, Lo L et al (2007) Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care 30:378–380PubMedCrossRef Xu L, McLennan SV, Lo L et al (2007) Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care 30:378–380PubMedCrossRef
26.
go back to reference Lipsky BA, Berendt AR, Embil J, de Lalla F (2004) Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 20:S56–S64PubMedCrossRef Lipsky BA, Berendt AR, Embil J, de Lalla F (2004) Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 20:S56–S64PubMedCrossRef
27.
go back to reference Dow G, Browne A, Sibald RG (1999) Infection in chronic wounds: controversies in diagnosis and treatment. Ostomy Wound Manage 45:23–40PubMed Dow G, Browne A, Sibald RG (1999) Infection in chronic wounds: controversies in diagnosis and treatment. Ostomy Wound Manage 45:23–40PubMed
28.
go back to reference Kerstein MD (1996) Wound infection: assessment and management. Wounds 8:141–144 Kerstein MD (1996) Wound infection: assessment and management. Wounds 8:141–144
Metadata
Title
Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study
Authors
A. Jeandrot
J.-L. Richard
C. Combescure
N. Jourdan
S. Finge
M. Rodier
P. Corbeau
A. Sotto
J.-P. Lavigne
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0840-8

Other articles of this Issue 2/2008

Diabetologia 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.